Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas

European Journal of Cancer

Volumn 35, Issue 7, 1999, Pages 1083-1088

  Broll, R ^a   Stark, A ^a   Windhovel U ^a   Best, R ^a   Strik, M W ^a   Schimmelpenning, H ^a   Schwandner, O ^a   Kujath, P ^a   Bruch, H P ^a   Duchrow, M ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Colorectal carcinomas; Distant metastases; Lymph node metastases; mdm2 oncogene; MRNA level protein level; TP53 tumour suppressor gene

Indexed keywords

MESSENGER RNA; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RNA ANALYSIS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033165975     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00058-1     Document Type: Article

References (33)

1. Fearon E.R., Vogelstein B. A genetic model for colorectal tumourigenesis. Cell. 61:1990;759-767.
2. Lane D.P. P53, guardian of the genome. Nature. 358:1992;15-16.
3. Finlay C.A. The mdm2-oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13:1993;301-306.
4. Momand J., Zambetti P., Olsen D.C., George D., Levine A.J. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
5. Chang F., Syrjänen S., Tervahauta A., Syrjänen K. Tumorigenesis associated with the p53 tumour suppressor gene. Br. J. Cancer. 68:1993;653-661.
6. Cahilly-Snyder L., Yang-Feng T., Francke U., George D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic. Cell. Mol. Genet. 13:1987;235-244.
7. Gorgoulis V.G., Zoumpourlis V., Rassidakis G.Z.et al. A molecular and immunohistochemical study of the mdm2 protein isoforms and p53 gene product in bronchogenic carcinoma. J. Pathol. 180:1996;129-137.
8. Barak Y., Gottlieb E., Juven-Gershon T., Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8:1994;1739-1749.
9. Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:1993;4107-4114.
10. Giannikaki E., Kouvidou C., Tzardi M.et al. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. Anticancer Res. 17:1997;2123-2127.
11. Midgley C.A., Lane D.P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15:1997;1179-1189.
12. Valassiadou K.E., Stefanaki K., Tzardi M.et al. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res. 17:1997;2571-2576.
13. Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
14. Öfner D., Maier H., Riedmann B.et al. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J. Clin. Pathol.: Mol. Pathol. 48:1995;M12-M16.
15. Hermanek P, Sobin LH, eds. TNM Classification of Malignant Tumours, 4th Edn, 2nd revision. Berlin, Springer, 1992.
16. Futreal P.A., Barret J.C., Wiseman R.W. An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res. 19:1991;6977.
17. Marchetti A., Buttitta F., Girlando S.et al. Mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J. Pathol. 175:1995;31-38.
18. El-Mahdani N., Vaillant J.C., Guiguet M.et al. Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br. J. Cancer. 75:1997;528-536.
19. Fu L., Minden M.D., Benchimol S. Translational regulation of human p53 gene expression. EMBO J. 15:1996;4392-4401.
20. Tomoda H., Kakeji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. J. Surg. Oncol. 58:1995;125-128.
21. Costa A., Marasca R., Valentinis B.et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J. Pathol. 176:1995;45-53.
22. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer. 57:1994;1-9.
23. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
24. Kressner U., Lindmark G., Gerdin B., Pahlman L., Glimelius B. Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 16:1996;951-958.
25. Purdie C.A., O'Grady J., Piris J., Wyllie A.H., Bird C.C. p53 expression in colorectal tumours. Am. J. Pathol. 138:1991;807-813.
26. Bertorelle R., Esposito G., Del Mistro A.et al. Association of p53 gene and protein alterations with metastasis in colorectal carcinomas. Am. J. Surg. Pathol. 19:1995;463-471.
27. Yamaguchi A., Nakagawara G., Kurosaka Y., Nishimura G., Yonemura Y., Miyazaki I. P53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br. J. Cancer. 68:1993;399-402.
28. Courjal F., Cuny M., Rodriguez C.et al. DNA amplifications at 30q13 and mdm2 define distinct subsets of evolved breast and ovarian tumours. Br. J. Cancer. 74:1996;1984-1989.
29. Reifenberger G., Liu L., Ichimura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:1993;2736-2739.
30. Wiethege T., Voss B., Müller K.M. Detection of MDM2-proto-oncogene in paraffin embedded human bronchial epithelium. J. Cancer Res. Clin. Oncol. 120:1994;252-255.
31. Maxwell S.A. Selective compartmentalization of different mdm2 proteins within the nucleus. Anticancer Res. 14:1994;2541-2548.
32. Ladanyi M., Cha C., Lewis R., Jhanwar S.C., Huvos A.G., Healey J.H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53:1993;16-18.
33. Patterson H., Gill S., Fisher C.et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br. J. Cancer. 69:1994;1052-1058.